LBF20207TX01: Difference between revisions
m (LBF20307TX01 moved to LBF20207TX01) |
No edit summary |
||
(7 intermediate revisions by the same user not shown) | |||
Line 6: | Line 6: | ||
|LipidBank=XPR2001 | |LipidBank=XPR2001 | ||
|LipidMaps=LMFA03030001 | |LipidMaps=LMFA03030001 | ||
|SysName=7- [ 3- ( | |SysName=7- [3- (3S-Hydroxy-trans-1-octenyl) - (1S,5S,4,6) -dioxabicyclo [ 3.1.1 ] hept-2-yl] -cis-5-heptenoic acid | ||
|Common Name=&& | |Common Name=&&Thromboxane A_2&&7- [ 3- (3 (S) -Hydroxy-1 (E) -octenyl) -1 (S) ,5 (S) ,4,6-dioxabicyclo [ 3.1.1 ] hept-2-yl ] -5 (Z) -heptenoic acid&& | ||
|Source=Thromboxane A2 is produced in platelets, polymorphonuclear leukocytes, macrophages, lung, kidney and spleen of various animals upon various biological stimulations [[Reference:Moncada_S:Vane_JR:,Pharmacol. Rev.,1978,30,293|{{RelationTable/GetFirstAuthor|Reference:Moncada_S:Vane_JR:,Pharmacol. Rev.,1978,30,293}}]]. | |Source=Thromboxane A2 is produced in platelets, polymorphonuclear leukocytes, macrophages, lung, kidney and spleen of various animals upon various biological stimulations [[Reference:Moncada_S:Vane_JR:,Pharmacol. Rev.,1978,30,293|{{RelationTable/GetFirstAuthor|Reference:Moncada_S:Vane_JR:,Pharmacol. Rev.,1978,30,293}}]]. | ||
|Chemical Synthesis= | |Chemical Synthesis= |
Latest revision as of 07:05, 21 October 2010
LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
IDs and Links | |
---|---|
LipidBank | XPR2001 |
LipidMaps | LMFA03030001 |
CAS | |
KEGG | {{{KEGG}}} |
KNApSAcK | {{{KNApSAcK}}} |
mol | LBF20207TX01 |
Thromboxane A2 | |
---|---|
Structural Information | |
7- [3- (3S-Hydroxy-trans-1-octenyl) - (1S,5S,4,6) -dioxabicyclo [ 3.1.1 ] hept-2-yl] -cis-5-heptenoic acid | |
| |
TXA2 | |
Formula | C20H32O5 |
Exact Mass | 352.224974134 |
Average Mass | 352.46508 |
SMILES | C(CC[C@@H](O)C=C[C@H]([C@@H](CC=CCCCC(O)=O)1)O[C@H](C2)O[C@@H]12)CC |
Physicochemical Information | |
Thromboxane A2 is produced in platelets, polymorphonuclear leukocytes, macrophages, lung, kidney and spleen of various animals upon various biological stimulations Moncada_S et al.. | |
Prostaglandin H2 produced by the catalysis of cyclooxygenase is further metabolized to thrombaxne A2 by thromboxane synthaase. Thromboxane A2 is unstable (half life 30 sec) and its oxetane ring is hydrolyzed to hemiacetal thromboxane B2 Needleman_P et al.. The major urinary metabolite of tromboxane B2 is 2,3-dinor-thromboxane B2 Kindahl_H , and 11-dehydro-thromboxane B2 is known as a suitble parameter for monitoring thromboxane production in human Westlund_P et al.. | |
Thromboxane A2 aggregates platelets and constricts blood vessels and bronchi Whittle_BJ et al.. Thromboxane A2 binds to a specific recptor (TP) coupled to Gq protein Ushikubi_F et al.. | |
cDNA and genomic DNA for thromboxane A synthase Tanabe_T et al. and those fro thromboxane A2 receptor Ushikubi_F et al. were cloned. | |
Stability:unstable in water around neutrality with a half life of about 40 sec at 37°C and decomposes to TXB2 and 12-hydroxy-5,8,10-heptadecatrienoic acid Moncada_S et al.. | |
Spectral Information | |
Mass Spectra | |
UV Spectra | |
IR Spectra | |
NMR Spectra | |
Other Spectra | |
Chromatograms |
Reported Metabolites, References | |||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|